Inventor · disambiguated record
Edmund K. Waller
Also filed as: WALLER EDMUND · WALLER EDMUND K
14 granted patents·13 pending applications·116 citations·filing 1995–2024
90Inventor score
Top patents by PatentIndex Score
27 records- 0189US6517830B1Compositions and methods for the expression of factor VIII polypeptides and uses thereforUNIV EMORY·Filed 2000·Granted Feb 11, 2003·21 cites·12 claims
- 0284US5800539AMethod of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host diseaseUNIV EMORY·Filed 1995·Granted Sep 1, 1998·65 cites·20 claims
- 0383US9458217B2Methods of managing graft versus host diseaseUNIV EMORY·Filed 2014·Granted Oct 4, 2016·7 cites·5 claims
- 0480US9669092B2Antagonism of the VIP signaling pathwayWALLER EDMUND K·Filed 2012·Granted Jun 6, 2017·4 cites·7 claims
- 0577US2025122258A1Compositions and uses of vasoactive intestinal peptide (vip) antagonistsUNIV EMORY·Filed 2024·Application pending·0 cites
- 0674US11850263B2Nanoparticles conjugated with vasoactive intestinal peptide antagonistsUNIV EMORY·Filed 2018·Granted Dec 26, 2023·1 cites·10 claims
- 0772US11859208B2Methods of treating cancer using cell based therapiesUNIV EMORY·Filed 2017·Granted Jan 2, 2024·1 cites·13 claims
- 0872US2023293681A1Antagonism of the VIP Signaling PathwayUNIV EMORY·Filed 2022·Application pending·0 cites
- 0971US12098180B2Compositions and uses of vasoactive intestinal peptide (VIP) antagonistsUNIV EMORY·Filed 2019·Granted Sep 24, 2024·0 cites·6 claims
- 1068US8486408B2Methods for the treatment of graft-versus-host diseaseHOSSAIN MOHAMMAD S·Filed 2009·Granted Jul 16, 2013·4 cites·14 claims
- 1168US2024066101A1VIP and VIP Agonists, Nanoparticles, and Uses in Inflammatory T-Cell Mediated DiseaseUNIV EMORY·Filed 2023·Application pending·0 cites
- 1266US2024271092A1Methods of Treating Cancer and Infectious Diseases Using Cell Based TherapiesUNIV EMORY·Filed 2023·Application pending·0 cites
- 1364US11786580B2VIP and VIP agonists, nanoparticles, and uses in inflammatory T-cell mediated diseaseUNIV EMORY·Filed 2019·Granted Oct 17, 2023·0 cites·3 claims
- 1461US11471506B2VIP antagonists and uses in treating cancerUNIV EMORY·Filed 2019·Granted Oct 18, 2022·0 cites·15 claims
- 1561US2025144138A1Chimeric Antigen Receptor Therapies and Vasoactive Intestinal Peptide Receptor AntagonistsUNIV EMORY·Filed 2022·Application pending·0 cites
- 1659US2023190865A1VIP Antagonists and Uses in Treating CancerUNIV EMORY·Filed 2022·Application pending·0 cites
- 1758US2024247048A1Vasoactive intestinal peptide (vip) receptor antagonistsUNIV EMORY·Filed 2022·Application pending·0 cites
- 1855US11464855B2Antagonism of the VIP signaling pathwayUNIV EMORY·Filed 2017·Granted Oct 11, 2022·0 cites·7 claims
- 1955US2021393720A1Hair Growth CompositionsWALLER EDMUND·Filed 2021·Application pending·0 cites
- 2055US2003129174A1Compositions and methods for the expression of factor VIII polypeptides and uses thereforUNIV EMORY·Filed 2002·Application pending·0 cites
- 2147US2005013810A1Regulating immune response using dendritic cellsFiled 2002·Application pending·0 cites
- 2245US2001014320A1Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activityUNIV EMORY·Filed 2000·Application pending·0 cites
- 2342US6213127B1Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activityUNIV EMORY·Filed 1996·Granted Apr 10, 2001·7 cites·44 claims
- 2438US2002127208A1Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host diseaseFiled 2001·Application pending·0 cites
- 2538US2003007968A1Methods of inducing organ transplant tolerance and correcting hemoglobinopathiesFiled 2002·Application pending·0 cites
- 2637US10154989B2Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereofUNIV EMORY·Filed 2016·Granted Dec 18, 2018·0 cites·10 claims
- 2732US6060643AMouse model with human immune systemUNIV EMORY·Filed 1995·Granted May 9, 2000·6 cites·27 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →